Earlier this month, a senior executive at Sun Pharmaceuticals (SUNPHARMA), one of the world’s largest purveyors of generic drugs, and his wife settled insider trading allegations brought by Indian regulators. The case stemmed from an episode five years ago, when Abhay Gandhi traded in Ranbaxy Laboratories stock soon after Sun Pharma agreed to buy the company from another drug maker.

Despite the infraction, Gandhi remains with the company as both head of its North American operations and as a director of Taro Pharmaceuticals, in which Sun Pharma owns a controlling stake. Meanwhile, a just few days after he and his wife agreed to pay $100,000 to settle the case, Sun Pharma sent an email to employees about a new policy to make it easier for whistleblowers to convey information about insider trading.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Kudos to our scribe for making prompt use of the newly enhanced FDA website. Typing in “SUN” got prompt responses – although I seem to have observed 7 inspection reports for four different sites?

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy